Management of Complications of Prostate Cancer Treatment

Michaelson, M. Dror; Cotter, Shane E.; Gargollo, Patricio C.; Zietman, Anthony L.; Dahl, Douglas M.; Smith, Matthew R.

doi:10.3322/ca.2008.0002

Cited by 161 publications

(155 citation statements)

References 156 publications

(139 reference statements)

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…Although the mechanism of androgen dependence in prostate tumor growth is not fully understood, the primary goal of treatment for prostate cancer in the clinic is to achieve suppression or inhibition of AR activation by androgen deprivation through surgical castration, estrogen, antiandrogens, or their combination (reviewed in ref. 3). Androgen ablation by either surgical castration or by luteinizing hormone-releasing hormone analogue strongly inhibits the growth of localized advanced cancer by eliminating circulating testosterone (4,5).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in aPten-Deficient Mouse Model of Prostate Cancer

Zhang¹,

Zhu²,

Efferson³

et al. 2009

Cancer Research

View full text Add to dashboard Cite

Androgen receptors have been shown to play a critical role in prostate cancer. We used ultrasound imaging techniques to track tumor response to antiandrogen and rapamycin treatment in a prostate-specific Pten-deleted mouse model of cancer. Depletion of androgens by either surgical or chemical castration significantly inhibited tumor growth progression without altering the activation of Akt and mammalian target of rapamycin (mTOR). We also showed for the first time that targeting mTOR along with antiandrogen treatment exhibited additive antitumor effects in vivo when compared with single agents. Our preclinical data suggest that combination of antiandrogens with mTOR inhibitors might be more effective in treating androgen-dependent prostate cancer patients. [Cancer Res 2009;69(18):7466-72]

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in aPten-Deficient Mouse Model of Prostate Cancer

Zhang¹,

Zhu²,

Efferson³

et al. 2009

Cancer Research

View full text Add to dashboard Cite

show abstract

“…Unfortunately, these therapies are often associated with unique and varying degrees of debilitating physiological and psychological side effects that can negatively impact a patient's quality of life (QOL). [1][2][3] Morbidity not withstanding, the efficacy of primary PC therapy is limited as one in three men will develop a PC recurrence despite aggressive local therapy. 4,5 For men with recurrent PC, androgen deprivation therapy (ADT) has been shown to dramatically reduce tumor burden; however, it has been associated with reduced libido, lean muscle mass and bone density.…”

Section: Introductionmentioning

confidence: 99%

Exercise therapy across the prostate cancer continuum

Antonelli

Freedland

Jones

2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Exercise has been increasingly investigated as an adjunct therapy for cancer patients. The purpose of this paper is to comprehensively review the literature regarding exercise as a therapeutic adjunct for prostate cancer (PC). Several studies in patients with PC have shown quality of life improvements associated with exercise. Although no study has established the effect of exercise as a monotherapy for PC, the molecular mechanisms responsible for the potential association between exercise and PC are being elucidated. Given the low-risk, high-reward nature of these studies, further investigations are needed to better define the function of exercise along the PC continuum.

show abstract

“…Patients with radiation-induced dysuria describe symptoms of burning or pain with urination. The etiology of radiation-induced dysuria is unknown, but may involve inflammation and mucosal loss at the urethra and bladder neck (6). The risk of dysuria appears to be dependent upon a number of factors, including the prostate volume, the volume of the urethra receiving a high-radiation dose, and delayed use of alpha-blockers (7,8).…”

Section: Sbrt-related Dysuriamentioning

confidence: 99%

“…Dysuria is a clinical problem associated with benign prostatic enlargement (BPH) and/or prostatitis (5). It is a commonly reported toxicity following pelvic radiation therapy and may be difficult to manage (6). Patients with radiation-induced dysuria describe symptoms of burning or pain with urination.…”

Section: Sbrt-related Dysuriamentioning

confidence: 99%